FEATURES
Samsung invests in Flagship Pioneering Fund VIII
Samsung C&T Corporation, Samsung Biologics, Samsung Bioepis and Samsung Venture Investment Corporation (collectively hereinafter referred to as “Samsung”) announced today an investment into Flagship Pioneering Fund VIII (“Fund VIII”) to help fuel breakthrough innovations in human health and sustainability. In
Samsung C&T Q1 2024 earnings
Overall Performance Revenue: KRW 10.796T, Operating Profit: KRW 712B – Year-over-Year (YoY) comparison: Revenue increased by KRW 557B (5.4%) from KRW 10.239T in Q1 2023,operating profit increased by KRW 71B (11.1%) from KRW 641B in Q1 2023 – Quarter-over-Quarter (QoQ)
Samsung C&T to invest in future growth and enhance shareholder value on foundation of steady performance
– 2023 revenue KRW 41.896T, operating profit KRW 2.870T – Highest possible dividend payout under consistent dividend policy at KRW 2,550 per common stock and KRW 2,600 per preferred stock – Cancellation of treasury shares – 7,807,563 common shares (third
ABOUT SAMSUNG C&T
IN NUMBERS
As of 2023